Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Ar...
GlobeNewswire · 07/27 11:00
3 Biotech Stocks Wall Street Predicts Will Rally by More Than 170% · 07/22 10:22
BRIEF-Aravive Achieves Second Development Milestone From 3D Medicines · 07/15 11:23
Aravive Achieves Second Development Milestone from 3D Medicines
Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian CancerHOUSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage o...
GlobeNewswire · 07/15 11:00
Aravive Wins $3 Million Milestone for IND Approval of Oncology Drug Candidate in China
MT Newswires · 07/15 07:54
Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference
HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DBAT, Chief Executive Officer of Ar...
GlobeNewswire · 07/07 11:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 07/01 21:35
Hedge Fund Sentiment Is Stagnant On Aravive, Inc. (ARAV)
In this article we will take a look at whether hedge funds think Aravive, Inc. (NASDAQ:ARAV) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars...
Insider Monkey · 06/29 12:53
Aravive Shares Rise 8% After Positive Results for Kidney-Cancer Treatment · 06/24 17:05
Thinking about buying stock in Aravive, Marin Software, Staffing 360 Solutions, Corbus Pharmaceuticals, or Globalstar?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARAV, MRIN, STAF, CRBP, and GSAT.
PR Newswire - PRF · 06/24 15:00
Hot Stocks: earnings move RAD and ACN; drug development boosts LLY, RCUS, ARAV
PPAMPicture/E+ via Getty Images Earnings news is moving shares of some household names on Thursday morning in pre-market trading. Drug store chain Rite Aid (RAD) dropped following the release of
Seekingalpha · 06/24 13:14
FSLR, LLY, SNDL and BBBY among premarket gainers
Marin Software Incorporated (MRIN) +63% on new InstaCart Ad Integration.India Globalization Capital (IGC) +22% on Alzheimer’s drug trial update.GTT Communications (GTT) +21%.Aravive, Inc. (ARAV) +20% on early-stage kidney cancer study data.Arcus Bioscience...
Seekingalpha · 06/24 12:26
Aravive shares surge on early-stage kidney cancer study data
Aravive (ARAV) shares rise more than 27% premarket after announcing positive initial results from the Phase 1b portion of its early-stage study testing a combination of AVB-500 in patients with advanced stage kidney
Seekingalpha · 06/24 11:45
BRIEF-Aravive Announces Positive Initial Results From Phase 1B Portion Of The Phase1b/2 Study Of Avb-500 In Combination With Cabozantinib In Clear Cell Renal Carcinoma · 06/24 11:38
Aravive Reports Positive Results From Trial for Kidney Cancer Treatment · 06/24 11:31
Aravive Higher on Progress in Phase 1b Trial of Kidney-Cancer Drug
Aravive shares jumped after the oncology-drug specialist reported progress in a trial of a drug to treat kidney cancer. · 06/24 10:05
BRIEF-Aravive Announces Three New Appointments To Its Board Of Directors · 05/18 11:10
BRIEF-Aravive Reports Q1 Loss Per Share $0.44 · 05/06 11:52
Aravive EPS beats by $0.01, misses on revenue
Aravive (ARAV): Q1 GAAP EPS of -$0.44 beats by $0.01.Revenue of $0.26M misses by $0.09M.Press Release
Seekingalpha · 05/06 11:26
-- Earnings Flash (ARAV) ARAVIVE Reports Q1 Revenue $256,000
MT Newswires · 05/06 07:26
Webull provides a variety of real-time ARAV stock news. You can receive the latest news about Aravive Inc through multiple platforms. This information may help you make smarter investment decisions.
About ARAV
Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.